Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".
作者信息
Bernstein Daniel
机构信息
Cardiovascular Institute and Department of Pediatrics, Stanford University, Stanford, CA.
出版信息
Circ Res. 2018 Mar 30;122(7):e64-e65. doi: 10.1161/CIRCRESAHA.118.312921.
Abstract
摘要
相似文献
1
Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".伯恩斯坦对关于《蒽环类药物心脏毒性：是否令人担忧到让你颤抖？》这篇文章的信件的回复。
Circ Res. 2018 Mar 30;122(7):e64-e65. doi: 10.1161/CIRCRESAHA.118.312921.
2
Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".利普舒尔茨就《蒽环类药物心脏毒性：是否令人担忧到让你颤抖？》一文所写的信。
Circ Res. 2018 Mar 30;122(7):e62-e63. doi: 10.1161/CIRCRESAHA.118.312918.
3
Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?蒽环类药物心脏毒性：是否令人担忧到让你颤抖？
Circ Res. 2018 Jan 19;122(2):188-190. doi: 10.1161/CIRCRESAHA.117.312395.
4
[Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].[心脏肿瘤学：蒽环类药物毒性预防的当前研究进展]
Kardiologiia. 2016 Dec;56(12):72-79.
5
Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology.升级利用蒽环类药物：新的作用机制、毒理学和药理学。
Toxicol Appl Pharmacol. 2023 Jan 15;459:116362. doi: 10.1016/j.taap.2022.116362. Epub 2022 Dec 30.
6
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.蒽环类药物诱导的心脏毒性的病理生理学及预防策略
Korean J Intern Med. 2016 Jul;31(4):625-33. doi: 10.3904/kjim.2016.017. Epub 2016 Jul 1.
7
Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?蒽环类药物所致心脏毒性——我们即将清除这一障碍？
Eur J Cancer. 2023 May;185:94-104. doi: 10.1016/j.ejca.2023.02.019. Epub 2023 Feb 24.
8
Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.蒽环类和蒽醌等效比推导至多柔比星用于迟发性心脏毒性。
JAMA Oncol. 2019 Jun 1;5(6):864-871. doi: 10.1001/jamaoncol.2018.6634.
9
Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review.急性髓系白血病合并唐氏综合征患者蒽环类药物相关心脏毒性：文献综述
Cardiovasc Toxicol. 2016 Jan;16(1):5-13. doi: 10.1007/s12012-015-9307-1.
10
Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes.阿霉素相关性心肌病：我们现在在哪里？病理生理学、剂量建议、预后和结果的更新。
Curr Opin Cardiol. 2019 May;34(3):289-295. doi: 10.1097/HCO.0000000000000617.
引用本文的文献
1
A photochemical-responsive nanoparticle boosts doxorubicin uptake to suppress breast cancer cell proliferation by apoptosis.一种光化学响应性纳米颗粒通过促进阿霉素摄取来抑制乳腺癌细胞增殖并诱导细胞凋亡。
Sci Rep. 2022 Jun 20;12(1):10354. doi: 10.1038/s41598-022-14518-x.
2
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.预防癌症幸存者蒽环类药物所致心脏毒性的策略。
Cardiooncology. 2019 Dec 2;5:18. doi: 10.1186/s40959-019-0054-5. eCollection 2019.
本文引用的文献
1
Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?蒽环类药物心脏毒性：是否令人担忧到让你颤抖？
Circ Res. 2018 Jan 19;122(2):188-190. doi: 10.1161/CIRCRESAHA.117.312395.
2
Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.右丙亚胺对新诊断的T细胞急性淋巴细胞白血病或晚期淋巴细胞性非霍奇金淋巴瘤患者的心脏保护作用及安全性：儿童肿瘤协作组随机试验儿科肿瘤组9404报告
J Clin Oncol. 2016 Mar 10;34(8):854-62. doi: 10.1200/JCO.2015.60.8851. Epub 2015 Dec 23.
3
Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.蒽环类化疗药物中应用右丙亚胺的心脏保护作用及其与第二恶性肿瘤的相关性：系统评价与荟萃分析。
J Natl Cancer Inst. 2015 Nov 23;108(4). doi: 10.1093/jnci/djv357. Print 2016 Apr.
4
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.RARG基因中的一个编码变异赋予儿童癌症患者对蒽环类药物诱导的心脏毒性的易感性。
Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.
5
Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.右丙亚胺治疗后的晚期死亡率：来自儿童肿瘤学组的报告。
J Clin Oncol. 2015 Aug 20;33(24):2639-45. doi: 10.1200/JCO.2014.59.4473. Epub 2015 May 26.
6
The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.催化性拓扑异构酶II抑制剂右丙亚胺可诱导癌细胞中的DNA断裂、激活转录因子3（ATF3）以及引发DNA损伤反应。
Br J Pharmacol. 2015 May;172(9):2246-57. doi: 10.1111/bph.13046. Epub 2015 Feb 27.
7
Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients.小儿肿瘤患者中右丙亚胺暴露与继发性急性髓系白血病风险
Pediatr Blood Cancer. 2015 Apr;62(4):704-9. doi: 10.1002/pbc.25043. Epub 2014 Mar 26.
8
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.铁沉积病基因突变对蒽环类药物治疗的儿童高危白血病幸存者心脏状况的影响。
Cancer. 2013 Oct 1;119(19):3555-62. doi: 10.1002/cncr.28256. Epub 2013 Jul 16.
9
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.验证 SLC28A3 和 UGT1A6 中的变体是否可作为预测儿童蒽环类药物诱导性心脏毒性的遗传标志物。
Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. doi: 10.1002/pbc.24505. Epub 2013 Feb 25.
10
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.地塞米松磷酸钠治疗儿童急性淋巴细胞白血病继发急性髓系白血病发病率低：来自丹娜法伯癌症研究所 ALL 联盟的报告。
Eur J Cancer. 2011 Jun;47(9):1373-9. doi: 10.1016/j.ejca.2011.03.022. Epub 2011 Apr 20.
Zotero 插件